Logo image of CGON

CG ONCOLOGY INC (CGON) Stock Fundamental Analysis

NASDAQ:CGON - US1569441009 - Common Stock

25.86 USD
+0.44 (+1.73%)
Last: 8/26/2025, 10:20:56 AM
Fundamental Rating

3

Taking everything into account, CGON scores 3 out of 10 in our fundamental rating. CGON was compared to 547 industry peers in the Biotechnology industry. While CGON has a great health rating, there are worries on its profitability. While showing a medium growth rate, CGON is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CGON had negative earnings in the past year.
CGON had a negative operating cash flow in the past year.
CGON Yearly Net Income VS EBIT VS OCF VS FCFCGON Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

The Return On Assets of CGON (-18.26%) is better than 78.61% of its industry peers.
CGON has a better Return On Equity (-19.11%) than 85.74% of its industry peers.
Industry RankSector Rank
ROA -18.26%
ROE -19.11%
ROIC N/A
ROA(3y)-25.11%
ROA(5y)N/A
ROE(3y)-27.89%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CGON Yearly ROA, ROE, ROICCGON Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 -10 -20 -30 -40

1.3 Margins

CGON does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CGON Yearly Profit, Operating, Gross MarginsCGON Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 -10K -20K -30K

More info and screens

8

2. Health

2.1 Basic Checks

CGON does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CGON has been increased compared to 1 year ago.
CGON has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CGON Yearly Shares OutstandingCGON Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 20M 40M 60M
CGON Yearly Total Debt VS Total AssetsCGON Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

CGON has an Altman-Z score of 37.18. This indicates that CGON is financially healthy and has little risk of bankruptcy at the moment.
CGON has a better Altman-Z score (37.18) than 97.26% of its industry peers.
CGON has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 37.18
ROIC/WACCN/A
WACC9.72%
CGON Yearly LT Debt VS Equity VS FCFCGON Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

CGON has a Current Ratio of 22.15. This indicates that CGON is financially healthy and has no problem in meeting its short term obligations.
CGON has a Current ratio of 22.15. This is amongst the best in the industry. CGON outperforms 95.43% of its industry peers.
CGON has a Quick Ratio of 22.15. This indicates that CGON is financially healthy and has no problem in meeting its short term obligations.
CGON has a Quick ratio of 22.15. This is amongst the best in the industry. CGON outperforms 95.43% of its industry peers.
Industry RankSector Rank
Current Ratio 22.15
Quick Ratio 22.15
CGON Yearly Current Assets VS Current LiabilitesCGON Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

CGON shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -9.62%.
CGON shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -34.72%.
The Revenue for CGON have been decreasing by -52.09% on average. This is quite bad
EPS 1Y (TTM)-9.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-92.86%
Revenue 1Y (TTM)-34.72%
Revenue growth 3Y-52.09%
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, CGON will show a very strong growth in Earnings Per Share. The EPS will grow by 32.63% on average per year.
The Revenue is expected to grow by 276.70% on average over the next years. This is a very strong growth
EPS Next Y-54.53%
EPS Next 2Y-24.14%
EPS Next 3Y6.24%
EPS Next 5Y32.63%
Revenue Next Year-54.68%
Revenue Next 2Y921.58%
Revenue Next 3Y445.59%
Revenue Next 5Y276.7%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CGON Yearly Revenue VS EstimatesCGON Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
CGON Yearly EPS VS EstimatesCGON Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CGON reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CGON. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CGON Price Earnings VS Forward Price EarningsCGON Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CGON Per share dataCGON EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-24.14%
EPS Next 3Y6.24%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CGON!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CG ONCOLOGY INC

NASDAQ:CGON (8/26/2025, 10:20:56 AM)

25.86

+0.44 (+1.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-08 2025-08-08/bmo
Earnings (Next)11-10 2025-11-10
Inst Owners97.65%
Inst Owner Change5.73%
Ins Owners1.16%
Ins Owner Change0%
Market Cap1.97B
Analysts81.18
Price Target64.13 (147.99%)
Short Float %15.84%
Short Ratio12.53
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-12.35%
Min EPS beat(2)-15.32%
Max EPS beat(2)-9.38%
EPS beat(4)1
Avg EPS beat(4)-9.5%
Min EPS beat(4)-33.19%
Max EPS beat(4)19.89%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-88.02%
Min Revenue beat(2)-100%
Max Revenue beat(2)-76.04%
Revenue beat(4)1
Avg Revenue beat(4)65.12%
Min Revenue beat(4)-100%
Max Revenue beat(4)496.08%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)7.38%
PT rev (3m)0.4%
EPS NQ rev (1m)-23.37%
EPS NQ rev (3m)-23.64%
EPS NY rev (1m)-17.06%
EPS NY rev (3m)-19.32%
Revenue NQ rev (1m)-22.07%
Revenue NQ rev (3m)-52.21%
Revenue NY rev (1m)3.61%
Revenue NY rev (3m)-49.14%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3578.63
P/FCF N/A
P/OCF N/A
P/B 2.94
P/tB 2.94
EV/EBITDA N/A
EPS(TTM)-1.77
EYN/A
EPS(NY)-2.19
Fwd EYN/A
FCF(TTM)-1.23
FCFYN/A
OCF(TTM)-1.23
OCFYN/A
SpS0.01
BVpS8.79
TBVpS8.79
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -18.26%
ROE -19.11%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-25.11%
ROA(5y)N/A
ROE(3y)-27.89%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 118.41%
Cap/Sales 43.19%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 22.15
Quick Ratio 22.15
Altman-Z 37.18
F-Score3
WACC9.72%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-9.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-92.86%
EPS Next Y-54.53%
EPS Next 2Y-24.14%
EPS Next 3Y6.24%
EPS Next 5Y32.63%
Revenue 1Y (TTM)-34.72%
Revenue growth 3Y-52.09%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-54.68%
Revenue Next 2Y921.58%
Revenue Next 3Y445.59%
Revenue Next 5Y276.7%
EBIT growth 1Y-51.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-63.91%
EBIT Next 3Y25.78%
EBIT Next 5YN/A
FCF growth 1Y-72.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-72.32%
OCF growth 3YN/A
OCF growth 5YN/A